NASDAQ:SESN - Sesen Bio Stock Price, News & Analysis

$1.17
+0.03 (+2.63 %)
(As of 08/20/2019 03:02 PM ET)
Today's Range
$1.13
Now: $1.17
$1.17
50-Day Range
$1.09
MA: $1.21
$1.48
52-Week Range
$0.66
Now: $1.17
$2.60
Volume42,627 shs
Average Volume1.30 million shs
Market Capitalization$118.47 million
P/E RatioN/A
Dividend YieldN/A
Beta0.66
Sesen Bio, Inc, a late-stage clinical company, develops next-generation antibody-drug conjugate therapies for patients with cancer. It develops its products based on its Targeted Protein Therapeutics (TPTs) platform. The company's lead product candidate is Vicinium, a fusion protein that is in Phase III clinical trial for the treatment of high-grade non-muscle invasive bladder cancer. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SESN
CUSIPN/A
CIKN/A
Phone617-444-8550

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$430,000.00
Book Value$0.57 per share

Profitability

Net Income$-33,690,000.00

Miscellaneous

Employees24
Market Cap$118.47 million
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable

Receive SESN News and Ratings via Email

Sign-up to receive the latest news and ratings for SESN and its competitors with MarketBeat's FREE daily newsletter.


Sesen Bio (NASDAQ:SESN) Frequently Asked Questions

What is Sesen Bio's stock symbol?

Sesen Bio trades on the NASDAQ under the ticker symbol "SESN."

How were Sesen Bio's earnings last quarter?

Sesen Bio Inc (NASDAQ:SESN) released its quarterly earnings results on Thursday, August, 8th. The company reported ($0.13) EPS for the quarter, missing the Zacks' consensus estimate of ($0.09) by $0.04. View Sesen Bio's Earnings History.

When is Sesen Bio's next earnings date?

Sesen Bio is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for Sesen Bio.

What price target have analysts set for SESN?

3 analysts have issued 12 month price targets for Sesen Bio's stock. Their predictions range from $3.00 to $3.00. On average, they anticipate Sesen Bio's stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 156.4% from the stock's current price. View Analyst Price Targets for Sesen Bio.

What is the consensus analysts' recommendation for Sesen Bio?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sesen Bio in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sesen Bio.

What are Wall Street analysts saying about Sesen Bio stock?

Here are some recent quotes from research analysts about Sesen Bio stock:
  • 1. According to Zacks Investment Research, "Sesen Bio Inc. is a late-stage company developing next-generation antibody-drug conjugate therapies for patients with cancer. The company's product portfolio includes Vicinium(TM) which is in its clinical trial, treats high-grade non-muscle invasive bladder cancer. Sesen Bio Inc., formerly known as Eleven Biotherapeutics, is based in Massachusetts, United States. " (8/14/2019)
  • 2. HC Wainwright analysts commented, "We maintain our Neutral rating of SESN and our 12-month price target of $1.00 per share. We derive our price target based on a risk-adjusted NPV analysis of projected Vicinium and Proxinium revenues through 2030 assuming a 12% discount rate and a 3% terminal growth rate. We derive an rNPV of $45M for the products and add in cash and cash equivalents of $42M to arrive at a 12-month price target of $0.77 per diluted share, which we round to $1.00. (1) clinical; (2) regulatory; (3) commercial; (4) financial; and (5) intellectual property." (5/14/2019)

Has Sesen Bio been receiving favorable news coverage?

Media coverage about SESN stock has trended positive on Tuesday, InfoTrie Sentiment reports. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Sesen Bio earned a media sentiment score of 2.5 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the stock's share price in the near term. View News Stories for Sesen Bio.

Are investors shorting Sesen Bio?

Sesen Bio saw a decrease in short interest in the month of July. As of July 15th, there was short interest totalling 3,580,000 shares, a decrease of 26.1% from the June 15th total of 4,845,200 shares. Based on an average trading volume of 3,370,000 shares, the short-interest ratio is presently 1.1 days. Approximately 5.3% of the company's stock are short sold. View Sesen Bio's Current Options Chain.

Who are some of Sesen Bio's key competitors?

What other stocks do shareholders of Sesen Bio own?

Who are Sesen Bio's key executives?

Sesen Bio's management team includes the folowing people:
  • Mr. Richard F. Fitzgerald, CFO, Sec. & Treasurer (Age 55)
  • Dr. Thomas R. Cannell, Pres, CEO & Director (Age 57)
  • Dr. K. Christopher Garcia, Co-Founder & Member of Scientific Advisory Board
  • Dr. Gregory L. Verdine, Co-Founder (Age 60)
  • Dr. Casey T. Weaver, Co-Founder & Member of Scientific Advisory Board

Who are Sesen Bio's major shareholders?

Sesen Bio's stock is owned by many different of retail and institutional investors. Top institutional investors include CVI Holdings LLC (10.47%), Vanguard Group Inc. (4.59%), BlackRock Inc. (1.88%), Monashee Investment Management LLC (0.26%), Bank of New York Mellon Corp (0.14%) and Wells Fargo & Company MN (0.13%).

Which major investors are selling Sesen Bio stock?

SESN stock was sold by a variety of institutional investors in the last quarter, including Private Advisor Group LLC and WINTON GROUP Ltd.

Which major investors are buying Sesen Bio stock?

SESN stock was purchased by a variety of institutional investors in the last quarter, including CVI Holdings LLC, Monashee Investment Management LLC, Wells Fargo & Company MN, BlackRock Inc., Bank of New York Mellon Corp, Jane Street Group LLC, FNY Investment Advisers LLC and Vanguard Group Inc..

How do I buy shares of Sesen Bio?

Shares of SESN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sesen Bio's stock price today?

One share of SESN stock can currently be purchased for approximately $1.17.

How big of a company is Sesen Bio?

Sesen Bio has a market capitalization of $118.47 million and generates $430,000.00 in revenue each year. The company earns $-33,690,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis. Sesen Bio employs 24 workers across the globe.View Additional Information About Sesen Bio.

What is Sesen Bio's official website?

The official website for Sesen Bio is http://www.sesenbio.com/.

How can I contact Sesen Bio?

Sesen Bio's mailing address is 245 FIRST STREET SUITE 1800, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-444-8550 or via email at [email protected]


MarketBeat Community Rating for Sesen Bio (NASDAQ SESN)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  100 (Vote Outperform)
Underperform Votes:  93 (Vote Underperform)
Total Votes:  193
MarketBeat's community ratings are surveys of what our community members think about Sesen Bio and other stocks. Vote "Outperform" if you believe SESN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SESN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel